Use of Next Generation Sequencing and Synergy Susceptibility Testing in Diagnosis and Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Blood Stream Infection

<div>The results of synergy susceptibility testing. (a) Synergy susceptibility testing represented synergism between imipenem and ceftazidime (red square). CR-<i>Kp</i> was resistant to imipenem (blue square). (b) No synergism between imipenem and clavulanic acid (yellow square). CR-<i>Kp</i> was resistant to imipenem (blue square). CAZ, ceftazidime; IPM, imipenem; CLA, clavulanic acid.</div>

Case Reports in Infectious Diseases

fig2

Figure 2

Figure 2: Use of Next Generation Sequencing and Synergy Susceptibility Testing in Diagnosis and Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Blood Stream Infection 

Figure 2 | Use of Next Generation Sequencing and Synergy Susceptibility Testing in Diagnosis and Treatment of Carbapenem-Resistant Klebsiella pneumoniae Blood Stream Infection 